Monitoring disease progression and the effectiveness of cancer treatment
Signatera Signatera is a personalized circulating tumor DNA (ctDNA) test used in oncology monitoring and assessment of molecular residual disease (MRD).
ctDNA can be a useful biomarker for:
Signatera A personalized tumor-informed ctDNA assay
SignateraThe test is optimized to detect extremely low quantities of circulating tumor DNA (ctDNA) and to determine the presence or absence of molecular residual disease (MRD). It can detect as little as one genomic equivalent of tumor ctDNA in 10 mL of blood (VAF = 0.01%).
The assay uses personalized ultra-deep multiplex PCR-based next-generation sequencing (NGS).
Main testing stages
High potential Signatera has been studied in the following cancers:
In the validation studies cited on the original site, cancer recurrence was detected by Signatera on average:
|
How is the test performed?
STAGE 1.
Biological material: Paraffin block and/or histological slide
STAGE 2.
Venous blood collected in an EDTA tube
STAGE 3.
Analysis and creation of an individualized tumor profile
STAGE 4.
Reporting whether tumor ctDNA is detected in the bloodstream
STAGE 5.
Follow-up testing every 6–12 months (venous blood in an EDTA tube).
Initial test price (stages 1–4): For pricing information, please contact our consultant.
Sample required: Paraffin-embedded tumor tissue and venous EDTA blood
Cost of each follow-up test (stage 5): For pricing information, please contact our consultant.
Sample required: Venous blood in an EDTA tube
Have a question?
Let us discuss it. Complete the form and our specialist will answer your questions.
We serve patients across Georgia!